The U.S. government through the National Institutes of Health (NIH) has launched a public-private partnership to accelerate the development of life-saving drugs and to help identify new treatments and cures and help address today’s global public health challenges. The Accelerating Medicines Partnership (AMP) is cofounded by the NIH, ten leading pharmaceutical companies, and a number of nonprofit organizations and will invest $230 million over five years to support the large-scale characterization of the underlying pathology of Alzheimer's disease, type 2 diabetes, rheumatoid arthritis, and lupus.
Through this cross-sector partnership, which will be managed through the Foundation for the NIH (FNIH), NIH and industry partners are sharing expertise and resources through an integrated governance structure that enables the best informed contributions to science from all participants. A critical component of the partnership is that industry partners have agreed to make the AMP data and analyses publicly accessible to the broad biomedical community. These pilot projects will set the stage for broadening AMP to other diseases and conditions. The AMP includes: the U.S. Food and Drug Administration, the NIH, AbbVie, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Pfizer, Sanofi, Takeda and eight non-profit groups.
|Value||USD 230 Million|